FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of September 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AZN harmonises listing structure
29 September 2025
AstraZeneca to harmonise its listing structure across the London
Stock Exchange, Nasdaq Stockholm and New York Stock
Exchange
Harmonisation of listing structure requires a direct listing of
AstraZeneca shares on the NYSE in place of existing US
ADRs
AstraZeneca continues to be listed, headquartered and tax resident
in the UK
AstraZeneca plans to harmonise its share listing structure to
deliver a global listing for global investors in a global
company. The Board of AstraZeneca is recommending to
shareholders a Harmonised Listing Structure for the
Company's ordinary shares across the London Stock Exchange
(LSE), Nasdaq Stockholm (STO) and the New York Stock Exchange
(NYSE).
This requires upgrading AstraZeneca's existing US equity listing by
way of a direct listing of AstraZeneca ordinary shares on the NYSE,
replacing the existing US listing of AstraZeneca ADRs on Nasdaq.
Following implementation of the Harmonised Listing Structure,
shareholders will be able to trade their interests in AstraZeneca
ordinary shares across the LSE, STO and NYSE.
Michel Demaré, Chair, AstraZeneca said: "Today we set out our
proposed harmonised listing structure which will support our
long-term strategy for sustainable growth, while remaining
headquartered in the UK and listed in London, Stockholm and New
York. Enabling a global listing structure will allow us to reach a
broader mix of global investors and will make it even more
attractive for all our shareholders to have the opportunity to
participate in AstraZeneca's exciting future."
AstraZeneca's scientific and commercial achievements have been
underpinned by its continuous adaptation to a rapidly changing and
dynamic industry environment, including diversifying its access
paths to capital markets. The US has the world's largest and most
liquid public markets by capitalisation, and the largest pool of
innovative biopharma companies and investors. The Board is
determined to ensure that the AstraZeneca Group has the flexibility
to access the broadest available pool of capital, including in the
US, which today's announcement will make possible.
The Harmonised Listing Structure will not change AstraZeneca's
current status as a UK listed, headquartered and tax resident
company which will continue to be included in the FTSE 100 index
and the OMX Stockholm 30 index. The Company will remain bound by
applicable UK governance principles and standards (including the
Companies Act 2006 and the UK Corporate Governance Code) following
the implementation of the Harmonised Listing
Structure.
A Circular incorporating a notice of General Meeting and containing
further details regarding the proposed Harmonised Listing Structure
has been published on the Company's website
at https://www.astrazeneca.com/investor-relations/shareholder-information.html#2025-0 and
will shortly be made available to shareholders and persons with
information rights ahead of the general meeting of the Company to
be held on Monday 3 November 2025 at 2:30 p.m. (GMT). Full
details and joining instructions are set out in the
Circular.
Copies of the following documents have been submitted to the
National Storage Mechanism and will shortly be available for
inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism:
● Circular and notice of General
Meeting;
● Form of Proxy for the General
Meeting;
● the Company's existing articles of
association, marked up to
show the proposed changes; and
● the Company's proposed new articles of
association.
Cautionary statement regarding forward-looking
statements
This document contains certain forward-looking statements,
including, among other things, statements about the expected impact
of the Harmonised Listing Structure on AstraZeneca and shareholders
of AstraZeneca. Although the AstraZeneca Group believes its
expectations are based on reasonable assumptions, any
forward-looking statements, by their very nature, involve risks and
uncertainties and may be influenced by factors that could cause
actual outcomes and results to be materially different from those
predicted. The forward-looking statements reflect knowledge and
information available at the date of preparation of this document
and the AstraZeneca Group undertakes no obligation to update these
forward-looking statements. The AstraZeneca Group identifies the
forward-looking statements by using the words 'anticipates',
'believes', 'expects', 'intends', 'will' and similar expressions in
such statements.
Important factors that could cause actual results to differ
materially from those contained in forward-looking statements,
certain of which are beyond the AstraZeneca Group's control,
include, among other things: the risk of failure or delay in
delivery of pipeline or launch of new medicines; the risk of
failure to meet regulatory or ethical requirements for medicine
development or approval; the risk of failures or delays in the
quality or execution of the AstraZeneca Group's commercial
strategies; the risk of pricing, affordability, access and
competitive pressures; the risk of failure to maintain supply of
compliant, quality medicines; the risk of illegal trade in the
AstraZeneca Group's medicines; the impact of reliance on
third-party goods and services; the risk of failure in information
technology or cybersecurity; the risk of failure of critical
processes; the risk of failure to collect and manage data and
artificial intelligence in line with legal and regulatory
requirements and strategic objectives; the risk of failure to
attract, develop, engage and retain a diverse, talented and capable
workforce; the risk of failure to meet our sustainability targets,
regulatory requirements and stakeholder expectations with respect
to the environment; the risk of the safety and efficacy of marketed
medicines being questioned; the risk of adverse outcome of
litigation and/or governmental investigations; intellectual
property risks related to the AstraZeneca Group's products;
the risk of failure to achieve strategic plans or meet targets or
expectations; the risk of geopolitical and/or macroeconomic
volatility disrupting the operation of our global business; the
risk of failure in internal control, financial reporting or the
occurrence of fraud; and the risk of unexpected deterioration in
the AstraZeneca Group's financial position.
Notes
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca.
The contents of AstraZeneca's website do not form part of this
document and no one should rely on such websites or the contents
thereof in reading this document.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date: 29 September 2025
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|